Drug Profile
Research programme: neurological disorder therapeutics - Neuropore
Alternative Names: Alzheimer's disease therapeutic - Neuropore Therapies; Neurodegenerative disorder therapeutics - Neuropore TherapiesLatest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Neuropore Therapies
- Class Neuroprotectants; Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Neurodegenerative disorders
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 28 Oct 2020 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA
- 20 Sep 2016 Preclinical trials in Alzheimer's disease in USA (unspecified route)